62501-73-9

Upstream product

• 62501-72-8 (R)-2-hydroxymethyl-1,4-benzodioxane 
• 98-59-9 p-toluenesulfonyl chloride 
• 115563-61-6 (S)-1-(R)-2,3-Dihydro-benzo[1,4]dioxin-2-yl-2-propylamino-ethanol 
• 115563-60-5 (R)-1,4-benzodioxane-2-carboxaldehyde 
• 72522-21-5 (2R,1'S)-2-oxiranyl-1,4-benzodioxan 
• 164515-27-9 (2S)-1-(2'-benzyloxyphenoxy)-2-tosyloxy-3-benzyloxypropane 
• 164515-26-8 (2S)-1-(2'-benzyloxyphenoxy)-3-benzyloxy-2-propanol 
• 62501-71-7 (R)-2-benzyloxymethyl-2,3-dihydrobenzodioxane 
• 98572-00-0 (S)-2-hydroxymethyl-1,4-benzodioxane 

Downstream Products

• 115649-80-4 (-)-Spiroxatrine 
• 46049-48-3 (R)-2-((amino)methyl)-1,4-benzodioxane 
• 81602-24-6 (R)-WB-4101 

Relevant academic research and scientific papers

USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY

The present invention is a method for the treatment of anxiety and related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I)

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN

The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as desc

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS

The present invention is a method for treating, preventing, reversing, arresting or inhibiting the occurrence, development and maturation of seizures or seizure-related disorders. More specifically, the present invention is directed to methods for the use

CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS

The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS

The present invention is a method for the glucose related disorders and lipid related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION

The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) a

USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE

The present invention is a method for the treatment or prevention of migraine comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and fo

Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders

The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.

N-substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as 92 antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents

A series of N-substituted 1-(2,3-dihydro-1,4-benzodioxin-2- yl)methylamine derivatives with D2 antagonist/5-HT(1A) partial agonist activity has been prepared as potential atypical antipsychotic agents. Optimization of in vitro receptor binding activity and in vivo activity in rodent models of psychosis has led to compound 24, which showed good affinities for human D2, D3, and 5-HT(1A) receptors but significantly less affinity for human α1 adrenoceptors and rat H1 and muscarinic receptors. In rodents, 24 showed functional D2-like antagonism and 5-HT(1A) partial agonism. After oral dosing, 24 showed good activity in rodent antipsychotic tests and very little potential to cause extrapyramidal side effects (EPS), as measured by its ability to induce catalepsy in rats only at very high doses. In the light of this promising profile of activity, 24 has been selected for clinical investigation as a novel antipsychotic agent with a predicted low propensity to cause EPS.

Serotonergic Properties of Spiroxatrine Enantiomers

The neuroleptic drug spiperone (1) has proven very useful in the characterization of putative serotonin (5-hydroxytryptamine, 5-HT) receptors.Thus, 5-HT1 receptors have been divided into subtypes based on their affinities for 1: 5-HT1A/su